A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

Clinical trial NCT02335918 · COMPLETED

Trial details

NCT number: NCT02335918
Sponsor: Celldex Therapeutics
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Squamous Cell Carcinoma of the Head and Neck (SCCHN)Ovarian Carcinoma-Enrollment Completed Colorectal Cancer (CRC)-Enrollment Completed Renal Cell Carcinoma (RCC) (Phase ll Only)Glioblastoma (GBM) (Phase ll Only)-Enrollment Completed

Start date: 2015-01-01
Primary completion: 2018-12-12
Enrollment: 175

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.